59 assets in Classic Hodgkin Lymphoma

Therapeutic assets addressing Classic Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
cd30.car-ebvst cells Classic Hodgkin Lymphoma	Baylor College of Medicine	P1	CC (41)
mgd024 Classic Hodgkin Lymphoma	MacroGenics	P1	CC (41)
pf-08046032 Classic Hodgkin Lymphoma	Pfizer	P1	CC (41)
Anti-Pd-L1 Monoclonal Antibody Ck-301 Classic Hodgkin Lymphoma	Checkpoint Therapeutics, Inc.	P1	CC (40)
Fosifloxuridine Nafalbenamide Classic Hodgkin Lymphoma	NuCana plc	P1/2	C (39)
Magrolimab Classic Hodgkin Lymphoma	Ranjana Advani	P2	C (36)
Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) Classic Hodgkin Lymphoma	Sanofi	P2	D (31)
Sasanlimab Classic Hodgkin Lymphoma	Pfizer	P1	D (28)
Immunoglobulin G1-Kappa/Lambda, Anti-[Homo Sapiens Pdcd1 (Programmed Cell Death 1, Pd1, Pd-1, Cd279) And Havcr2 (Hepatitis A Virus Cellular Receptor 2, T Cell Immunoglobulin And Mucin Domains Family Member 3, Tim3, Tim-3, Timd3, Cd366)], Humanized And Homo Sapiens Monoclonal Antibody, Bispecific, Bivalent Classic Hodgkin Lymphoma	AstraZeneca	P1	NR ()

Showing 51 to 59 of 59 assets

PreviousPage 2 of 2Next